Clinical Characteristics of 20 Patients With MF/SS
| Patient . | Age/Sex . | Clinical . | Leukocyte Count . | Sézary Cell Count . | Therapy . | Survival* . |
|---|---|---|---|---|---|---|
| No. . | . | Stage . | (×109/L) . | (×109/L) . | . | (mo) . |
| 1 | 66/M | III | 7.2 | <0.1 | PUVA, TS, NM, IFN | 26 |
| 2 | 60/F | IVA | 5.6 | 0.3 | PUVA, CHOP, M-BACOD, IFN | Alive (36+) |
| 3 | 38/F | III | 12.9 | 0.2 | TS | Alive (23+) |
| 4 | 53/F | IB | 7.6 | 0 | PUVA, TSEB, SS, IFN, NM | Alive (28+) |
| 5 | 31/M | IB | 6.1 | 0 | PUVA | NA |
| 6 | 42/F | IIB | 9.9 | 0.1 | NM, PUVA, IFN, CHOP, ESHP, HBR | 3.5 |
| 7 | 59/M | IA | 9.3 | 0 | TS, PUVA, IFN, COP, HBR | Alive (20+) |
| 8 | 65/F | III | 13.2 | 3.3 | None | Alive (17+) |
| 9 | 69/M | IVA | NA | NA | PUVA, IFN, TRA, Chl, SS | Alive (29+) |
| 10.5 | 3.9 | |||||
| 10 | 42/F | III | NA | 1.0 | TS, PUVA, IFN, MTX, SS | Alive (34+) |
| 16.0 | 5.6 | |||||
| 9.7 | 2.3 | |||||
| 11 | 79/F | III | NA | NA | UVB, TS, PUVA, Chl, SS | Alive (34+) |
| 7.1 | 0.6 | |||||
| 12 | 75/F | III | 10.9 | 0.7 | PUVA, MTX, VP-16, COP | Alive (32+) |
| 13 | 72/F | IVA | 27.2 | 3.6 | 2-CDA, TS | 0.25 |
| 14 | 71/M | IVA | 27.1 | 7.9 | TS, UV-B, PUVA, IFN, TRA, CHOP, SS | 22 |
| 15 | 78/F | III | 6.8 | 0.3 | PUVA, SS, TS, UVB | 2 |
| 16 | 60/M | III | 273 | 259.4 | MTX, PUVA, IFN, SS, Chl, PP, CHOP, DAB, 2CDA, hydroxyurea | 0 |
| 17 | 58/M | IVA | 34.9 | 17 | None | 3 |
| 18 | 79/M | III | 4.0 | 0.4 | 2-CDA, NM, PUVA | 2 |
| 19 | 65/M | III | 20.9 | 8.8 | TS, PUVA | 6 |
| Patient . | Age/Sex . | Clinical . | Leukocyte Count . | Sézary Cell Count . | Therapy . | Survival* . |
|---|---|---|---|---|---|---|
| No. . | . | Stage . | (×109/L) . | (×109/L) . | . | (mo) . |
| 1 | 66/M | III | 7.2 | <0.1 | PUVA, TS, NM, IFN | 26 |
| 2 | 60/F | IVA | 5.6 | 0.3 | PUVA, CHOP, M-BACOD, IFN | Alive (36+) |
| 3 | 38/F | III | 12.9 | 0.2 | TS | Alive (23+) |
| 4 | 53/F | IB | 7.6 | 0 | PUVA, TSEB, SS, IFN, NM | Alive (28+) |
| 5 | 31/M | IB | 6.1 | 0 | PUVA | NA |
| 6 | 42/F | IIB | 9.9 | 0.1 | NM, PUVA, IFN, CHOP, ESHP, HBR | 3.5 |
| 7 | 59/M | IA | 9.3 | 0 | TS, PUVA, IFN, COP, HBR | Alive (20+) |
| 8 | 65/F | III | 13.2 | 3.3 | None | Alive (17+) |
| 9 | 69/M | IVA | NA | NA | PUVA, IFN, TRA, Chl, SS | Alive (29+) |
| 10.5 | 3.9 | |||||
| 10 | 42/F | III | NA | 1.0 | TS, PUVA, IFN, MTX, SS | Alive (34+) |
| 16.0 | 5.6 | |||||
| 9.7 | 2.3 | |||||
| 11 | 79/F | III | NA | NA | UVB, TS, PUVA, Chl, SS | Alive (34+) |
| 7.1 | 0.6 | |||||
| 12 | 75/F | III | 10.9 | 0.7 | PUVA, MTX, VP-16, COP | Alive (32+) |
| 13 | 72/F | IVA | 27.2 | 3.6 | 2-CDA, TS | 0.25 |
| 14 | 71/M | IVA | 27.1 | 7.9 | TS, UV-B, PUVA, IFN, TRA, CHOP, SS | 22 |
| 15 | 78/F | III | 6.8 | 0.3 | PUVA, SS, TS, UVB | 2 |
| 16 | 60/M | III | 273 | 259.4 | MTX, PUVA, IFN, SS, Chl, PP, CHOP, DAB, 2CDA, hydroxyurea | 0 |
| 17 | 58/M | IVA | 34.9 | 17 | None | 3 |
| 18 | 79/M | III | 4.0 | 0.4 | 2-CDA, NM, PUVA | 2 |
| 19 | 65/M | III | 20.9 | 8.8 | TS, PUVA | 6 |
Abbreviations: PUVA, oral Psoralen with ultraviolet A; TS, topical steroid; NM, nitrogen mustard; IFN, interferon-α; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; M-BACOD, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, leucovorin; TSEB, total skin electron beam; SS, systemic steroid; ESHAP, etoposide, solumedrol, ara-c, cis-platin; HBR, hemibody radiation; VP-16, etoposide; COP, cytoxine, vincristine, prednisone; TRA, trans-retinoic acid; Chl, chlorambucil; MTX, methotrexate; UVB, ultraviolet B.
Since cytogenetic investigation.